CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Recruiting

Phase 1

CRISPR-Edited CAR-TCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Sponsor:

Caribou Biosciences, Inc.

Code:

NCT06752876

Conditions

Systemic Lupus Erythematosus

Lupus

Lupus Erythematosus

Lupus Nephritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CB-010

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Caribou Biosciences, Inc. on 2025-04-17.